|
🐜
|
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
28 auth.
N. Munshi,
L. Anderson,
N. Shah,
D. Madduri,
J. Berdeja,
S. Lonial,
N. Raje,
Yi Lin,
D. Siegel,
A. Oriol,
P. Moreau,
I. Yakoub-Agha,
M. Delforge,
M. Cavo,
H. Einsele,
...
H. Goldschmidt,
K. Weisel,
A. Rambaldi,
D. Reece,
F. Petrocca,
M. Massaro,
Jamie N. Connarn,
S. Kaiser,
P. Patel,
Liping Huang,
T. Campbell,
K. Hege,
J. San-Miguel
|
10 |
2021 |
10
🐜
|
|
🐜
|
Anti‐BCMA CAR T‐Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
23 auth.
N. Raje,
J. Berdeja,
Yi Lin,
D. Siegel,
S. Jagannath,
D. Madduri,
M. Liedtke,
J. Rosenblatt,
M. Maus,
Ashley Turka,
...
L. Lam,
R. Morgan,
Kevin G. Friedman,
M. Massaro,
Julie Wang,
G. Russotti,
Zhihong Yang,
T. Campbell,
K. Hege,
F. Petrocca,
Travis Quigley,
N. Munshi,
J. Kochenderfer
|
10 |
2019 |
10
🐜
|
|
🦁
|
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
36 auth.
J. Berdeja,
D. Madduri,
S. Usmani,
A. Jakubowiak,
M. Agha,
A. Cohen,
A. Stewart,
P. Hari,
M. Htut,
A. Lesokhin,
A. Deol,
N. Munshi,
E. O’Donnell,
D. Avigan,
I. Singh,
...
E. Zudaire,
T. Yeh,
A. Allred,
Y. Olyslager,
A. Banerjee,
Carolyn C. Jackson,
J. Goldberg,
J. Schecter,
W. Deraedt,
S. Zhuang,
J. Infante,
D. Geng,
Xiaoling Wu,
M. Carrasco-Alfonso,
M. Akram,
F. Hossain,
Syed W H Rizvi,
F. Fan,
Yi Lin,
T. Martin,
S. Jagannath
|
9 |
2021 |
9
🦁
|
|
🐜
|
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
32 auth.
S. Lonial,
B. Weiss,
S. Usmani,
S. Singhal,
A. Chari,
N. Bahlis,
A. Belch,
A. Krishnan,
R. Vescio,
M. Mateos,
A. Mazumder,
R. Orlowski,
H. Sutherland,
J. Bladé,
E. Scott,
...
A. Oriol,
J. Berdeja,
M. Gharibo,
D. Stevens,
R. LeBlanc,
M. Sebag,
N. Callander,
A. Jakubowiak,
D. White,
J. Rubia,
P. Richardson,
S. Lisby,
Huaibao Feng,
C. Uhlar,
I. Khan,
T. Ahmadi,
P. Voorhees
|
9 |
2016 |
9
🐜
|
|
🐜
|
The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
21 auth.
E. Stein,
G. Garcia-Manero,
D. Rizzieri,
R. Tibes,
J. Berdeja,
M. Savona,
Mojca Jongen-Lavrenic,
J. Altman,
B. Thomson,
S. Blakemore,
...
S. Daigle,
N. Waters,
A. Suttle,
A. Clawson,
R. Pollock,
A. Krivtsov,
S. Armstrong,
J. Dimartino,
E. Hedrick,
B. Löwenberg,
M. Tallman
|
8 |
2018 |
8
🐜
|
|
🐜
|
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.
35 auth.
J. Hillengass,
S. Usmani,
S. Rajkumar,
B. Durie,
M. Mateos,
S. Lonial,
C. João,
K. Anderson,
R. García-Sanz,
E. R. Serra,
J. Du,
N. V. D. van de Donk,
J. Berdeja,
E. Terpos,
E. Zamagni,
...
R. Kyle,
J. S. San Miguel,
H. Goldschmidt,
S. Giralt,
Shaji K. Kumar,
N. Raje,
H. Ludwig,
E. Ocio,
R. Schots,
H. Einsele,
F. Schjesvold,
Wenming Chen,
N. Abildgaard,
B. Lipe,
D. Dytfeld,
B. Wirk,
M. Drake,
M. Cavo,
J. Lahuerta,
S. Lentzsch
|
8 |
2019 |
8
🐜
|
|
🐜
|
Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up
28 auth.
T. Martin,
S. Usmani,
J. Berdeja,
M. Agha,
A. Cohen,
P. Hari,
D. Avigan,
A. Deol,
M. Htut,
A. Lesokhin,
N. Munshi,
E. O’Donnell,
A. Stewart,
J. Schecter,
J. Goldberg,
...
Carolyn C. Jackson,
T. Yeh,
A. Banerjee,
A. Allred,
E. Zudaire,
W. Deraedt,
Y. Olyslager,
Changwei Zhou,
L. Pacaud,
D. Madduri,
A. Jakubowiak,
Yi Lin,
S. Jagannath
|
8 |
2022 |
8
🐜
|
|
🐜
|
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
22 auth.
P. Rodríguez-Otero,
S. Ailawadhi,
B. Arnulf,
K. Patel,
M. Cavo,
A. Nooka,
S. Manier,
N. Callander,
L. Costa,
R. Vij,
...
N. Bahlis,
P. Moreau,
S. Solomon,
M. Delforge,
J. Berdeja,
A. Truppel-Hartmann,
Zhihong Yang,
L. Favre‐Kontula,
Fan Wu,
J. Piasecki,
M. Cook,
S. Giralt
|
8 |
2023 |
8
🐜
|
|
🐜
|
Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma.
20 auth.
A. Chari,
M. Minnema,
J. Berdeja,
A. Oriol,
N. V. D. van de Donk,
P. Rodríguez-Otero,
E. Askari,
M. Mateos,
L. Costa,
J. Caers,
...
R. Verona,
S. Girgis,
Shiyi Yang,
R. Goldsmith,
Xiang Yao,
K. Pillarisetti,
B. Hilder,
Jeffery Russell,
J. Goldberg,
A. Krishnan
|
8 |
2022 |
8
🐜
|
|
🐜
|
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study.
19 auth.
Shaji K. Kumar,
J. Berdeja,
R. Niesvizky,
S. Lonial,
J. Laubach,
M. Hamadani,
A. Stewart,
P. Hari,
V. Roy,
R. Vescio,
...
J. Kaufman,
D. Berg,
E. Liao,
A. Di Bacco,
Jose Estevam,
N. Gupta,
A. Hui,
V. Rajkumar,
P. Richardson
|
7 |
2014 |
7
🐜
|
|
🐜
|
Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML.
17 auth.
R. Swords,
S. Coutre,
M. Maris,
J. Zeidner,
J. Foran,
J. Cruz,
H. Erba,
J. Berdeja,
W. Tam,
S. Vardhanabhuti,
...
Iwona Pawlikowska-Dobler,
H. Faessel,
Ajeeta B. Dash,
F. Sedarati,
B. Dezube,
D. Faller,
M. Savona
|
7 |
2018 |
7
🐜
|
|
🐜
|
Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial.
16 auth.
A. Yee,
W. Bensinger,
J. Supko,
P. Voorhees,
J. Berdeja,
P. Richardson,
E. Libby,
Ellen E. Wallace,
Nicole E Birrer,
Jill N. Burke,
...
D. Tamang,
Min Yang,
Simon S. Jones,
C. Wheeler,
R. Markelewicz,
N. Raje
|
7 |
2016 |
7
🐜
|
